- Home
- LPTX vs ZNTL Comparison
LPTX vs ZNTL Comparison
Compare LPTX & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTX
- ZNTL
- Stock Information
- Founded
- LPTX 2011
- ZNTL 2014
- Country
- LPTX United States
- ZNTL United States
- Employees
- LPTX N/A
- ZNTL N/A
- Industry
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- LPTX Health Care
- ZNTL Health Care
- Exchange
- LPTX Nasdaq
- ZNTL Nasdaq
- Market Cap
- LPTX 119.6M
- ZNTL 105.8M
- IPO Year
- LPTX N/A
- ZNTL 2020
- Fundamental
- Price
- LPTX $0.33
- ZNTL $1.33
- Analyst Decision
- LPTX Hold
- ZNTL Buy
- Analyst Count
- LPTX 1
- ZNTL 7
- Target Price
- LPTX N/A
- ZNTL $8.60
- AVG Volume (30 Days)
- LPTX 3.3M
- ZNTL 1.4M
- Earning Date
- LPTX 08-11-2025
- ZNTL 08-08-2025
- Dividend Yield
- LPTX N/A
- ZNTL N/A
- EPS Growth
- LPTX N/A
- ZNTL N/A
- EPS
- LPTX N/A
- ZNTL N/A
- Revenue
- LPTX N/A
- ZNTL $26,865,000.00
- Revenue This Year
- LPTX N/A
- ZNTL N/A
- Revenue Next Year
- LPTX N/A
- ZNTL N/A
- P/E Ratio
- LPTX N/A
- ZNTL N/A
- Revenue Growth
- LPTX N/A
- ZNTL N/A
- 52 Week Low
- LPTX $0.22
- ZNTL $1.01
- 52 Week High
- LPTX $4.79
- ZNTL $5.44
- Technical
- Relative Strength Index (RSI)
- LPTX 48.69
- ZNTL 50.91
- Support Level
- LPTX $0.28
- ZNTL $1.15
- Resistance Level
- LPTX $0.36
- ZNTL $1.38
- Average True Range (ATR)
- LPTX 0.04
- ZNTL 0.10
- MACD
- LPTX 0.01
- ZNTL 0.01
- Stochastic Oscillator
- LPTX 39.43
- ZNTL 75.00
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.